Year End Update on “Road to Cure Parkinson’s”

year-endYEAR END UPDATE ON “ROAD TO CURE PARKINSON’S” PROJECT THE SAN DIEGO BIOTECH COMPANY (SDBC)

 

The management of the San Diego Biotech Company (SDBC) has every reason to thank God for His grace and its investors whose financial contributions have enabled the accomplishment of key scientific objectives in 2012. These scientific objectives could have profound impact in the way neurodegenerative conditions are diagnosed and treated in the future. Incidentally, these are the scientific accomplishments, which the big pharmaceutical companies and private foundations, (e. g. MJFF), have been struggling to accomplish for many years with hundreds of millions of US dollars invested in such programs. These scientific objectives are:

  1. Development of technology to transport drugs across the impermeable blood-brain barrier (BBB), which has been one of the major obstacles to diagnosing and treating diseases of the central nervous system (CNS) such as Alzheimer’s disease (AD) and Parkinson’s diseases (PD).
  2. Third party validation of technology by Prof. Eliezer Masliah at UCSD in the transgenic mouse models for AD and PD.
  3. Precise targeting of AD and PD pathological protein targets in the brain of the transgenic mice.
  4. Achievement of these objectives with about $1.5M in total cost. Foundations and big pharmaceutical companies might have spent billions of US dollars without success so far.

What is Next?

The Company is establishing collaborations with national and international organizations for optimization of its technology to develop commercial diagnostic and therapeutic products for AD and PD. Some of these organizations are:

  1. The Van Andel Research Institute, Michigan
  2. Capital Management University, Beijing, China
  3. UCLA, Los Angeles, CA
  4. McGill University, Canada

Road Blocks:

While we enjoyed success in the science we had control over, there have been areas where we have been less fortunate. These areas are:

  1. Funding
  2. Obtaining transgenic mice, a near total ban on “for Profit” entities for purchasing

Corrective Measures:

  1. Hired Dr. Brian Davies, MD, MBA, to work upon Company Presentation and Documents so that SDBC can be presented to Institutional Investors.
  2. Appointed Dr. Arvind Bhambri, Professor at USC Marshal Business School, as an Advisor to SDBC’s Board of Directors to strengthen the Business segment of SDBC.
  3. Made arrangements to license transgenic mice for AD and PD from John Hopkins University (USA) and McGill University (Canada).

Projections:

The Company anticipates that with $5M each for AD and PD, respectively, it could conduct all the pre-clinical trials and start testing its picobodies in Alzheimer’s and Parkinson’s patients for diagnosing and treating patients in less than two years’ time. First focus is on diagnosing the disease. The Company feels that it already has a diagnostic test for AD and PD on hand because of the success it had with the transgenic mice models. With some optimization of its technology, first to market diagnostic tests for AD and PD are clearly in reach as the “lowest hanging fruits” for SCBC. For this reason, the Company is setting up collaboration with organizations that have PET imaging facilities.

Mark your calendars:

Saturday, May 4, 2013, join us for “ON THE ROAD TO THE CURE” Symposium at the Renaissance Esmeralda Hotel in Indian Wells (Palm Springs area), CA. Watch the Parkinson’s Resource Organization newsletter NEWSWORTHY NOTES and its website www.ParkinsonsResource.Org for updates. Symposium vendors and sponsors, please contact the PRO office.

About Editor